Dabigatran in the ischemic patient undergoing atrial fibrillation ablation

Dabigatran nel paziente ischemico sottoposto ad ablazione di fibrillazione atriale

  • Roberto Spoladore Unità di Terapia Intensiva Coronarica, Ospedale San Raffaele, Milano
Keywords: Atrial fibrillation, Dabigatran, Transcatheter ablation, Transient ischemic attack

Abstract

Trans-catheter ablation of atrial fibrillation (AF) is a common treatment for symptomatic AF. Among the major complications of AF ablation are stroke, transient ischemic attacks and peri-procedural cardiac tamponade. Various clinical trials have shown that uninterrupted treatment with vitamin K antagonists (VKA) is associated with a lower incidence of embolic events compared to discontinuation of therapy; until recently, in the absence of equally solid evidence, this practice was not extended to the new oral anticoagulants (NOAC) not VKA due to the fear of hemorrhagic complications potentially associated with the use of an "irreversible" anticoagulant. The case of a patient suffering from numerous comorbidities is reported here. In light of the poor response to anti-arrhythmics, a TC-RF ablation was performed, with suspension of dabigatran administration only on the day of the procedure (for a total period <24 hours). Although the fear of the risk of bleeding potentially associated with the trans-catheter ablation procedure may still induce clinicians to stop anticoagulant therapy, even the decision to discontinue anticoagulant therapy with dabigatran on the day of surgery alone is challenged by recent evidence in the literature supporting the efficacy of dabigatran in reducing the incidence of hemorrhagic events during and after ablation, including the results of the RE-CIRCUIT study (Cardiology)

Published
2018-10-04
How to Cite
SpoladoreR. (2018). Dabigatran in the ischemic patient undergoing atrial fibrillation ablation. AboutOpen, 4(1), 154-157. https://doi.org/10.19156/abtpn.2018.0065